721401-53-2Relevant articles and documents
Hydrolytic degradation study of rivaroxaban: Degradant products identification by LC-MS isolation by Prep-HPLC and characterization by HRMS, NMR and FT-IR
Mahesh Kumar Reddy,Korupolu, Raghu Babu,Kishore Babu,Murty Singamsetti,Rumalla, Chidananda Swamy,Kaliyaperumal, Muralidharan,Doddipalla, Raju,Vijay, Rajani
, p. 3035 - 3042 (2021/01/06)
Present work illustrates the stress degradation behaviour of rivaroxaban under hydrolytic, oxidative, thermal and photolytic conditions as per ICH guidelines. Under thermal and photolytic conditions drug had a fair stability where as in other stress conditions degradation products were observed. Initial identification of the degradation products was performed by hyphenated mass spectrometry coupled to ultra-performance liquid chromatography (UPLC-MS) and mass directed auto purification (MDAP) was used for isolation. Various 1D and 2D nuclear magnetic resonance (NMR) were performed to characterize the degradation products which were assisted by FT-IR and HRMS data. Two novel degradant products were observed in hydrolytic conditions, isolated and characterized by spectroscopic techniques as (R)-2-(2-((4-((3-(5-chlorothiophene-2-carboxamido)-2-hydroxypropyl)amino)phenyl)amino)ethoxy)acetic acid (DP-2) (m.w. of 427.90 g/mol and m.f. C18H22N3O5SCl), and 5-chlorothiophene-2-carboxylic acid (DP-3) (m.w. 161.95 g/mol and m.f. C5H3O2SCl). Additionally, two more degradation products were observed in basic and acidic conditions, viz. (R)-5-chloro-N-(2-hydroxy-3-((4-(3-oxomorpholino)phenyl)amino)propyl)thiophene-2-carboxamide (DP-1) (m.w. 409.09 g/mol and m.f. C18H20N3O4SCl) and (S)-2-(2-((4-(5-((5-chlorothiophene-2-carboxamido)methyl)-2-oxooxazolidin-3-yl)phenyl)amino)ethoxy)acetic acid (DP-4) (m.w. 453.08g /mol and m.f. C19H20N3O6SCl) are already reported.
Rivaroxaban thiophene carboxylate impurity reference substance and preparation method thereof
-
Paragraph 0022-0024, (2020/07/21)
The invention discloses a synthesis method of a rivaroxaban thiophene carboxylate impurity. The full name of the impurity is: 1-amino-3 ((4-(3-oxomorpholino) phenyl) amino) prop-2-yl 5-chlorothiophene-2-carboxylic acid ethyl ester hydrochloride. The invention also discloses a preparation method of the rivaroxaban thiophene carboxylate impurity. The preparation method comprises the following steps:dissolving rivaroxaban oxazolidine in an organic solvent, carrying out ring opening under the action of an acidic solution to obtain a rivaroxaban thiophene carboxylate impurity crude product, and recrystallizing with the organic solvent to obtain the high-purity rivaroxaban thiophene carboxylate impurity reference substance. The rivaroxaban thiophene carboxylate impurity is simple in preparationprocess and high in purity, and a qualified rivaroxaban thiophene carboxylate impurity reference substance can be provided for quality control of rivaroxaban.
A method for preparing the advantage cuts down Sha Ban
-
Paragraph 0050, (2017/08/25)
The invention discloses a preparation method of rivaroxaban, belonging to the field of chemical synthesis of medicine. The preparation method of rivaroxaban comprises the following steps: reacting 5-chlorothiophene-2-carboxylic acid-[(s)-2,3-dyhydroxy propyl]-amide with iodine under the catalytic action of triphenylphosphine and imidazole to produce 5-chlorothiophene-2-carboxylic acid-[(s)-3-iodo-2-hydroxy propyl]-amide; then reacting 5-chlorothiophene-2-carboxylic acid-[(s)-3-iodo-2-hydroxy propyl]-amide with 4-(4-aminophenyl)-3-morpholinone to produce 5-chlorothiophene-2-carboxylic acid{(R)-2-hydroxy-3-[4-(3-oxomorpholine-4-yl) phenyl amino]-propyl} amide; and finally introducing CO2 to react to produce rivaroxaban. The preparation method provided by the invention has the advantages that expensive and poisonous raw materials are not used, the production cost is low, the production safety is high, the environment pollution is hardly caused. Therefore, the preparation method is suitable for industrial production.